IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM

BACKGROUND: Immune checkpoint inhibitors (ICIs) are not uniformly effective in glioblastoma treatment. Immunogenomic determinants may identify patients who are most likely to benefit from these therapies. Therefore, we compared the immunogenomic phenotype of a responder to combination anti-LAG-3 and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Jackson, Christina, Choi, John, Zhang, JiaJia, Piotrowski, Anna, Walbert, Tobias, Desai, Arati, Ahluwalia, Manmeet, Nabors, Burt, Ye, Xiaobu, Desideri, Serena, Fisher, Joy, Wen, Patrick, Grossman, Stuart, Smith, Kellie, Pardoll, Drew, Lim, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847812/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.511
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados